Prakt. Lékáren. 2019; 15(2e): e11-e20 [Interní Med. 2018; 20(5): 247-252]
Osteoporosis – 1st part, etiopathogenesis, risk factors and diagnostics
- Ústav farmakologie LF UP a FN Olomouc
Osteoporosis is considered to be a disease prevails highly not only in the most developed industrial countries. As a chronic disease of the skeleton it is characterised by the decrease of bone density with deterioration of bone microstructure. Lowered bone strength is a result of quantitative and qualitative changes in the bone mass and this contributes to higher risk of fractures. Creation of the highest level of bone mass is the most important preventative factor. This can be achieved by consistent and appropriate physical activity and sufficient nutrition high in calcium, vitamin D and proteins. The diagnosis of osteoporosis is achieved either by laboratory tests, or mainly by dual-energy X-ray absorptiometry. Amongst women osteoporosis is mainly caused by estrogenic deficits. Among men the cause is mainly due to lack of testosterone. Secondary osteoporosis is caused mainly by glucocorticoid therapy, malnutrition, immobility, liver disease and kidney disease.
Keywords: bone, osteoporosis, risk factors, diagnostics
Published: June 20, 2019 Show citation
References
- Broulík P. Význam suplementace kalcia a vitaminu D v léčbě osteoporózy. Remedia 2016; 26(1): 62-66.
- Dostupné z: www.iofbonehealth.org, online dne 16. 2. 2018
- Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd. Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res. 2014; 29(3): 581-589.
Go to original source... 
Go to PubMed... - Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011; 22(5): 1277-1288. Go to original source...
- Horák P. Struktura kosti, léčba osteoporózy a hojení zlomenin. Interní Med 2012; 14(11): 441-442.
- Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in male physiology. Physiol Rev 2017; 97: 995-1043. Go to original source... Go to PubMed...
- Gennari L, Khosla S, Bilezikian JP. Estrogen and fracture risk in men. J Bone Miner Res. 2008; 23(10): 1548-1551. Go to original source... Go to PubMed...
- Rosa J. Osteoporóza u mužů. Osteologický bulletin 2016; 21(2): 42-48.
- Marek J a kolektiv autorů. Farmakoterapie vnitřních nemocí. Grada, 2010, s 417-425.
- Franceschi R, Vincenzi M, Camilot M et al. Idiopathic Juvenile Osteoporosis: Clinical Experience from a Single Centre and Screening of LRP5 and LRP6 Genes. Calcif Tissue Int. 2015; 96(6): 575-579. Go to original source... Go to PubMed...
- Gajic-Veljanoski O, Papaioannou A, Kennedy C, Ioannidis G, Berger C, et al. Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study. BMC Geriatr. 2018; 18(1): 4. Go to original source... Go to PubMed...
- Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Casta?eda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017; Dec 7. pii: S0049-0172(17)30649-2.
- Štěpán J. Osteoporóza, chronický zánět, mikrobiom a estrogeny. Remedia 2018; 28(1): 28-34.
- Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. 2009; 94(5):1483-1490. Go to original source...
- Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res. 2014; 29(1): 223-233. Go to original source... Go to PubMed...
- Yang S, Lix LM, Yan L, Hinds AM, Leslie WD. International Classification of Diseases (ICD)-coded obesity predicts risk of incident osteoporotic fracture. PLoS One. 2017; 12(12): e0189168. Go to original source... Go to PubMed...
- Ni Y, Fan D. Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies Medicine (Baltimore). 2017; 96(51): e8811. Go to original source... Go to PubMed...
- van Staa TP. The patogenesis, epidemiology and management og glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79(3): 129-137. Go to original source... Go to PubMed...
- Sutter SA, Stein EM. The Skeletal Effects of Inhaled Glucocorticoids. Curr Osteoporos Rep. 2016; 14(3): 106-113. Go to original source... Go to PubMed...
- Bruy?re O, Bergmann P, Cavalier E, Gielen E, Goemaere S et al. Skeletal health in breast cancer survivors. Maturitas. 2017; 105: 78-82. Go to original source... Go to PubMed...
- Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D et al. Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10): 3621-3634. Go to original source...
- Fojtík P, Urban O, Falt P, Novosad P. Výživa a sekundární osteoporóza. Interní Med. 2009; 11(12): 561-568.
- Bartl R. Osteopatie indukovaná antiepileptiky - formy, patogeneze, prevence, časná diagnóza a léčba. Medicína po promoci 5/2007.
- Stepan JJ, Vaculik J, Pavelka K, Zofka J, Johansson H et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int. 2012; 90(5): 365-372. Go to original source... Go to PubMed...
- Broulík P. Osteoporóza a její léčba. Praha: Maxdorf, 2009.
- Marshall WJ, Lapsley M, Day A, Ayling R Clinical Biochemistry: Metabolic and Clinical Aspects 3rd ed. Churchill Livingston, Londýn 2014, s. 614-621.
- Micozkadioglu H, Ozelsancak R, Yildiz I, Erken E, Zumrutdal A et al. Circadian rhythm of serum phosphate, calcium and parathyroid hormone levels in hemodialysis patients. Clin Lab. 2013; 59(1-2): 79-84. Go to original source... Go to PubMed...
- Hrdý P, Novosad P. Léčba osteoporózy - současné možnosti. Med. praxi 2011; 8(12): 523-527
- Pikner R. Laboratorní vyšetření v klinické osteologii. In: Džupa V, Jenšovský J, eds. Diagnostika a léčba osteoporózy a dalších onemocnění skeletu. Karolinum 2018:48-62 (ISBN 978-80-2463741-9)